Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation
By Ian Walker
Sandoz Group said that it has reached agreement with Amgen in the patent dispute over the company's denosumab biosimilars products, paving the way for it to launch its bone treatments Jubbonti and Wyost in the U.S. by May 31.
The Swiss pharmaceutical company didn't disclose any terms of the agreement but said it doesn't impact previously disclosed guidance for this year. It said on March 31 that the company expects 2024 net sales to grow mid-single digit in constant currencies.
Sandoz received U.S. Food and Drug Administration approval for Wyost and Jubbonti--the first denosumab biosimilars to treat skeletal-related events and osteoporosis--on March 5.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
April 30, 2024 02:02 ET (06:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks